Next Article in Journal
Participatory Workflow Analysis of Newborn Genetic Screening (NBS) to Support Tools for Improved Follow-Up: Comparing the Use Case of Hemoglobinopathy Traits Across U.S. States
Next Article in Special Issue
Evaluation of Cystic Fibrosis Newborn Screening and Follow-Up Process in Georgia (2022–2023)
Previous Article in Journal
Newborn Screening for Congenital Heart Disease: A Five-Year Study in Shanghai
Previous Article in Special Issue
India: The Last and Best Frontier for Cystic Fibrosis Newborn Screening with Perspectives on Special Challenges
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Commentary

It Takes All of Us: How the Cystic Fibrosis Foundation Is Supporting States in Advancing Cystic Fibrosis Newborn Screening

The Cystic Fibrosis Foundation, Bethesda, MD 20814, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2025, 11(2), 39; https://doi.org/10.3390/ijns11020039
Submission received: 20 March 2025 / Revised: 15 May 2025 / Accepted: 18 May 2025 / Published: 20 May 2025

Abstract

The publication of Cystic Fibrosis Newborn Screening: A Systematic Review-Driven Consensus Guideline from the United States Cystic Fibrosis Foundation (CFF) presents the challenge of implementation. CFF is prepared to partner with stakeholders to enhance newborn screening (NBS) practices. Through funding provided to the Center for Public Health Innovation (CPHI), the CFF has helped establish two genetic testing resource centers to help states implement CFTR sequencing within the NBS algorithm. CPHI, with CFF funding, is facilitating quality improvement collaboratives that unite CF clinicians and NBS staff nationwide to share best practices in laboratory methods, communication, and education. CFF continues to fund the Screening Improvement Program Award for Optimizing the Diagnosis of Infants and has developed a toolkit to help CF care teams collaborate with NBS programs on guideline implementation. Together, these initiatives aim to support states and CF providers in adapting their algorithms and processes. By identifying current best practices to improve timeliness, sensitivity, and equity in CF NBS, CFF seeks to promote better outcomes for all individuals with CF. Recognizing the competing demands on state public health departments, CFF is committed to partnering with stakeholders to ensure meaningful improvements in CF NBS.
Keywords: cystic fibrosis; newborn screening; newborn; neonatal screening; CFTR; sequencing; immunoreactive trypsinogen; IRT; guideline; genetic testing cystic fibrosis; newborn screening; newborn; neonatal screening; CFTR; sequencing; immunoreactive trypsinogen; IRT; guideline; genetic testing

Share and Cite

MDPI and ACS Style

Dwight, M.; Faro, A. It Takes All of Us: How the Cystic Fibrosis Foundation Is Supporting States in Advancing Cystic Fibrosis Newborn Screening. Int. J. Neonatal Screen. 2025, 11, 39. https://doi.org/10.3390/ijns11020039

AMA Style

Dwight M, Faro A. It Takes All of Us: How the Cystic Fibrosis Foundation Is Supporting States in Advancing Cystic Fibrosis Newborn Screening. International Journal of Neonatal Screening. 2025; 11(2):39. https://doi.org/10.3390/ijns11020039

Chicago/Turabian Style

Dwight, Mary, and Albert Faro. 2025. "It Takes All of Us: How the Cystic Fibrosis Foundation Is Supporting States in Advancing Cystic Fibrosis Newborn Screening" International Journal of Neonatal Screening 11, no. 2: 39. https://doi.org/10.3390/ijns11020039

APA Style

Dwight, M., & Faro, A. (2025). It Takes All of Us: How the Cystic Fibrosis Foundation Is Supporting States in Advancing Cystic Fibrosis Newborn Screening. International Journal of Neonatal Screening, 11(2), 39. https://doi.org/10.3390/ijns11020039

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop